Press release
Breast Cancer Biomarker Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Sermonix Pharmaceuticals, Novartis, Pfizer
The latest healthcare forecast report provides an in-depth analysis of Breast Cancer Biomarker, offering comprehensive insights into the Breast Cancer Biomarker revenue trends, prevalence, and treatment landscape. The report delves into key Breast Cancer Biomarker statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Breast Cancer Biomarker therapies. Additionally, we cover the landscape of Breast Cancer Biomarker clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Breast Cancer Biomarker treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Breast Cancer Biomarker space.
To Know in detail about the Breast Cancer Biomarker market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Breast Cancer Biomarker Market Forecast
https://www.delveinsight.com/sample-request/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Breast Cancer Biomarker Market Report:
• The Breast Cancer Biomarker market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In November 2024, Puma Biotechnology has launched the Phase II ALISCA-Breast1 trial to assess oral alisertib, a selective aurora kinase A inhibitor, for treating breast cancer. The trial will evaluate alisertib in combination with endocrine therapy for patients with hormone receptor-positive (HR+), HER2-negative recurrent or metastatic breast cancer who previously received treatment with CDK4/6 inhibitors and endocrine therapy.
• The overall market size for ER+/HER2- breast cancer in the 7MM was around USD 7,400 million in 2022 and is expected to grow throughout the forecast period (2023-2032).
• The existing treatment market for ER+/HER2- Breast Cancer in the adjuvant and neoadjuvant settings includes aromatase inhibitors, tamoxifen, chemotherapy, the CDK4/6 inhibitor Verzenio, among others. In 2019, the total treatment market for ER+/HER2- Breast Cancer in the US was estimated at around USD 6,300 million.
• In 2022, the market size for ER+/HER2- breast cancer in the first-line setting in the United States was approximately USD 3,800 million and is expected to grow over the forecast period (2023-2032).
• ORSERDU is the first endocrine breakthrough in 20 years, targeting ESR1 mutations in ER+, HER2-, advanced, or metastatic breast cancer patients whose disease has progressed after at least one line of endocrine therapy.
• Key Breast Cancer Biomarker Companies: AstraZeneca, Sermonix Pharmaceuticals, Novartis, Pfizer, and others
• Key Breast Cancer Biomarker Therapies: Camizestrant (AZD9833), Lasofoxifene, KISQALI (ribociclib), LYNPARZA (olaparib), FASLODEX (fulvestrant), IBRANCE (palbociclib), and others
• The Breast Cancer Biomarker market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Breast Cancer Biomarker pipeline products will significantly revolutionize the Breast Cancer Biomarker market dynamics.
• In 2023, approximately 297,790 new cases of breast cancer in women are expected to be diagnosed in the United States.
• Breast cancer ranks as the most common cancer among women in the United States, aside from skin cancers. It accounts for around 30% (or 1 in 3) of all newly diagnosed cancers in women each year. About 0.5-1% of breast cancer cases are found in men.
• The HR+/HER2- subtype of breast cancer is the most prevalent, with an age-adjusted incidence rate of 87.2 new cases per 100,000 women in the United States.
• In the United States, breast cancer cases are predominantly seen in postmenopausal women, accounting for approximately 80-20% of the total cases, whereas premenopausal women represent a much smaller share of the patient population.
• Among the different subtypes of the disease (localized and regional), ER+/HER2- had the largest patient population, with around 140,000 cases reported in 2022. This was followed by approximately 24,000 cases of Triple-negative and about 20,000 cases of ER+/HER2+. Meanwhile, HR-/HER2+ accounted for the fewest cases.
Breast Cancer Biomarker Overview
A breast cancer biomarker is a biological molecule found in blood, tissue, or other body fluids that indicates the presence or behavior of breast cancer. Biomarkers can help diagnose the disease, predict its progression, and guide treatment decisions. Common breast cancer biomarkers include hormone receptors (like estrogen and progesterone receptors), HER2 protein, and BRCA gene mutations. These markers are crucial for selecting targeted therapies and personalizing patient care.
Get a Free sample for the Breast Cancer Biomarker Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Breast Cancer Biomarker Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Breast Cancer Biomarker Epidemiology Segmentation:
The Breast Cancer Biomarker market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Breast Cancer Biomarker
• Prevalent Cases of Breast Cancer Biomarker by severity
• Gender-specific Prevalence of Breast Cancer Biomarker
• Diagnosed Cases of Episodic and Chronic Breast Cancer Biomarker
Download the report to understand which factors are driving Breast Cancer Biomarker epidemiology trends @ Breast Cancer Biomarker Epidemiology Forecast
https://www.delveinsight.com/sample-request/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Breast Cancer Biomarker Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Breast Cancer Biomarker market or expected to get launched during the study period. The analysis covers Breast Cancer Biomarker market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Breast Cancer Biomarker Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Breast Cancer Biomarker Therapies and Key Companies
• Camizestrant (AZD9833): AstraZeneca
• Lasofoxifene: Sermonix Pharmaceuticals
• KISQALI (ribociclib): Novartis
• LYNPARZA (olaparib): AstraZeneca
• FASLODEX (fulvestrant): AstraZeneca
• IBRANCE (palbociclib): Pfizer
Discover more about therapies set to grab major Breast Cancer Biomarker market share @ Breast Cancer Biomarker Treatment Landscape
https://www.delveinsight.com/sample-request/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Breast Cancer Biomarker Market Drivers
• Advancements in Technology
• Rising Incidence of Breast Cancer
• Personalized Medicine
• Rising Awareness
• Government Support
• Regulatory Approvals
Breast Cancer Biomarker Market Barriers
• High Costs
• Complexity in Biomarker Validation
• Lack of Standardization
• Regulatory Hurdles
• Limited Awareness in Low-Income Regions
• Data Privacy and Ethical Concerns
Scope of the Breast Cancer Biomarker Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Breast Cancer Biomarker Companies: AstraZeneca, Sermonix Pharmaceuticals, Novartis, Pfizer, and others
• Key Breast Cancer Biomarker Therapies: Camizestrant (AZD9833), Lasofoxifene, KISQALI (ribociclib), LYNPARZA (olaparib), FASLODEX (fulvestrant), IBRANCE (palbociclib), and others
• Breast Cancer Biomarker Therapeutic Assessment: Breast Cancer Biomarker current marketed and Breast Cancer Biomarker emerging therapies
• Breast Cancer Biomarker Market Dynamics: Breast Cancer Biomarker market drivers and Breast Cancer Biomarker market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Breast Cancer Biomarker Unmet Needs, KOL's views, Analyst's views, Breast Cancer Biomarker Market Access and Reimbursement
To know more about Breast Cancer Biomarker companies working in the treatment market, visit @ Breast Cancer Biomarker Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/breast-cancer-biomarker-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Breast Cancer Biomarker Market Report Introduction
2. Executive Summary for Breast Cancer Biomarker
3. SWOT analysis of Breast Cancer Biomarker
4. Breast Cancer Biomarker Patient Share (%) Overview at a Glance
5. Breast Cancer Biomarker Market Overview at a Glance
6. Breast Cancer Biomarker Disease Background and Overview
7. Breast Cancer Biomarker Epidemiology and Patient Population
8. Country-Specific Patient Population of Breast Cancer Biomarker
9. Breast Cancer Biomarker Current Treatment and Medical Practices
10. Breast Cancer Biomarker Unmet Needs
11. Breast Cancer Biomarker Emerging Therapies
12. Breast Cancer Biomarker Market Outlook
13. Country-Wise Breast Cancer Biomarker Market Analysis (2019-2032)
14. Breast Cancer Biomarker Market Access and Reimbursement of Therapies
15. Breast Cancer Biomarker Market Drivers
16. Breast Cancer Biomarker Market Barriers
17. Breast Cancer Biomarker Appendix
18. Breast Cancer Biomarker Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Latest Reports by DelveInsight
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
• Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market
• Neuroendoscopy Market: https://www.delveinsight.com/report-store/neuroendoscopy-market
• Nosocomial Infections Market: https://www.delveinsight.com/report-store/nosocomial-infections-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Breast Cancer Biomarker Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Sermonix Pharmaceuticals, Novartis, Pfizer here
News-ID: 3993409 • Views: …
More Releases from DelveInsight Business Research
Anti-CD19 Antibody Pipeline 2025: Therapies Under Investigation, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Anti-CD19 Antibody pipeline constitutes 12+ key companies continuously working towards developing 12+ Anti-CD19 Antibody treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Anti-CD19 Antibody Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anti-CD19 Antibody Market.
The Anti-CD19…
EGFR Non Small Cell Lung Cancer Pipeline 2025: MOA and ROA Insights, Clinical Tr …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, EGFR Non Small Cell Lung Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ EGFR Non Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The EGFR Non Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products…
Intrahepatic Cholangiocarcinoma Pipeline 2025: FDA Updates, Therapy Innovations, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 18+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report…
Atopic Dermatitis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Ev …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 120+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
More Releases for Breast
Breast Health Monitoring App Market to Witness a Pronounce Growth during 2024-20 …
The latest market intelligence report published by WMR with the title "Global Breast Health Monitoring App Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Healthcare and Pharmaceuticals industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report on Breast Health Monitoring App Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y…
Primary Breast Cancer Survivor Phil Alderson Shines Light on Male Breast Cancer …
FOR IMMEDIATE RELEASE
Primary Breast Cancer Survivor Phil Alderson Shines Light on Male Breast Cancer During Breast Cancer Awareness Month
Liverpool, UK - October, 2023 - Phil Alderson, a primary survivor of male breast cancer, is taking bold steps this Breast Cancer Awareness Month to raise awareness of this often overlooked aspect of the disease. With a homemade cardboard sign that reads "Check Your Pecks," Phil has taken to the streets of…
Breast Health Monitoring App Market Recent Trends, In-depth Analysis, Size, and …
According to The Worldwide Market Reports, the Latest research report on "Breast Health Monitoring App Market Size, Revenue, Global Analysis, and Forecast 2023 to 2030" The Breast Health Monitoring App Market research study is a professional report with premium insights into the size of the business, current patterns, drivers, risks, potential outcomes, and major segments. The Industry Report forecasts the future growth of the market based on precise assumptions. Furthermore,…
Breast Pumps Market - Nurturing Convenience: Revolutionizing Breast Pump Technol …
Newark, New Castle, USA - new report, titled Breast Pumps Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Breast Pumps market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Breast Pumps market. The report offers an overview of the market, which…
Breast Imaging Market by Breast Ultrasound, Breast MRI, Automated Whole-Breast U …
Growth of breast imaging market driven by factors like rising incidence of breast cancer globally, growing government investments and funding for breast cancer treatment and related research, increasing awareness about early detection of breast cancer, rising geriatric population, technological advancements in breast imaging modalities, and launch of advanced breast imaging systems capable of detecting cancer in women with dense breast tissues.
Download Free PDF Brochure on Brest Imaging Market Report Now…
Breast Implants Market Report 2018: Segmentation by Product (Silicone Breast Imp …
Global Breast Implants market research report provides company profile for Allergan, Mentor Worldwide LLC, Hans biomed, Establishment Labs, Polytech Health & Aesthetics, Sientra, Inc., GC Aesthetics, Cereplas and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to…
